-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 ODLl0AWzfHjyZ/Syj3IUTwMdmWVOJCJAZ85i+7OPiX6/fxTVvMzs+uJ3AoPSiWqk
 4qhctaFw9uBMVxrTvXlJOQ==

<SEC-DOCUMENT>0001047469-04-037765.txt : 20041221
<SEC-HEADER>0001047469-04-037765.hdr.sgml : 20041221
<ACCEPTANCE-DATETIME>20041221080558
ACCESSION NUMBER:		0001047469-04-037765
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041220
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041221
DATE AS OF CHANGE:		20041221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENZYME CORP
		CENTRAL INDEX KEY:			0000732485
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				061047163
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14680
		FILM NUMBER:		041215698

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQ
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6172527500

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2147860z8-k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04BOS2337_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P><FONT SIZE=2>
<hr noshade width=100% align=left size=4>
<hr noshade width=100% align=left size=1> </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<BR>
<P ALIGN="CENTER"><FONT SIZE=5><B>FORM 8-K  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>CURRENT REPORT  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B> PURSUANT TO SECTION&nbsp;13 OR 15(d)<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):<BR>
December 20, 2004  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=5><B>GENZYME CORPORATION<BR>  </B></FONT><FONT SIZE=2>(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="37%" ALIGN="CENTER"><FONT SIZE=2><B>Massachusetts<BR> </B></FONT><FONT SIZE=2>(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%" ALIGN="CENTER"><FONT SIZE=2><B>0-14680<BR> </B></FONT><FONT SIZE=2>(Commission<BR>
file number)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%" ALIGN="CENTER"><FONT SIZE=2><B>06-1047163<BR> </B></FONT><FONT SIZE=2>(IRS&nbsp;employer<BR>
identification&nbsp;number)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER"><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>500 Kendall Street, Cambridge, Massachusetts 02142<BR> </B></FONT><FONT SIZE=2>(Address of Principal Executive Offices) (Zip Code)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>Registrant's
telephone number, including area code:<BR></FONT> <FONT SIZE=2><B>(617)&nbsp;252-7500</B></FONT></P>

<P><FONT SIZE=2>Check
the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below.): </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD><FONT SIZE=2>Written
communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD><FONT SIZE=2>Soliciting
material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD><FONT SIZE=2>Pre-commencement
communications pursuant to Rule&nbsp;14-d-2(b) under the Exchange Act
(17&nbsp;CRF&nbsp;240.14d-2(b))
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></DT><DD><FONT SIZE=2>Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c)) under the Exchange Act
(17&nbsp;CFR&nbsp;240.13e-4(c)) </FONT></DD></DL>
<BR>

<P><FONT SIZE=2><hr
noshade width=100% align=left size=1>
<hr noshade width=100% align=left size=4> </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2147860",CP="GENZYME CORPORATION",DN="1",CHK=91125,FOLIO='blank',FILE='DISK009:[04BOS7.04BOS2337]BA2337A.;10',USER='CJOHNSOC',CD='20-DEC-2004;18:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->

<P><FONT SIZE=2><A
NAME="de2337_item_2.01._completion_of_acqui__ite02236"> </A>
<A NAME="toc_de2337_1"> </A>
<BR></FONT><FONT SIZE=2><B>Item 2.01. Completion of Acquisition or Disposition of Assets.    <BR>    </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 20, 2004 (the "Effective Date"), Genzyme Corporation ("Genzyme") completed the acquisition of ILEX Oncology,&nbsp;Inc. ("ILEX"), a publicly held
Delaware corporation, pursuant to the terms of an Agreement and Plan of Merger dated as of February&nbsp;26, 2004 (the "Merger Agreement") among Genzyme, GLBC Corp., a wholly-owned subsidiary of
Genzyme, GLBC LLC, a wholly-owned subsidiary of Genzyme, and ILEX. On the Effective Date, GLBC Corp. merged with and into ILEX, with ILEX continuing as the surviving company (the "First Merger"), and
ILEX subsequently merged with and into GLBC LLC, with GLBC LLC continuing as the surviving company and a wholly-owned subsidiary of Genzyme (the "Second Merger", and collectively with the First
Merger, the "Mergers"). The assets involved are used in the business of developing and commercializing therapeutic products, primarily in Onocology. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Merger Agreement and as a result of the First Merger, each share of ILEX common stock outstanding at the effective time of the First Merger was converted into the right
to receive 0.4682 of a share of Genzyme common stock. An aggregate of approximately 18,457,800 shares of Genzyme common stock are being issued as consideration. In addition, upon completion of the
Mergers, Genzyme assumed outstanding options to purchase shares of ILEX common stock, adjusted to reflect the exchange ratio referred to above. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of Genzyme common stock pursuant to the Merger Agreement as described above was registered under the Securities Act of 1933, as amended, pursuant to Genzyme's registration
statement on Form&nbsp;S-4 (File No.&nbsp;333-114184) (the "Registration Statement") filed with the Securities and Exchange Commission (the "SEC") on April&nbsp;5, 2004,
as amended by Amendment No.&nbsp;1 thereto and declared effective on May&nbsp;28, 2004. The Proxy Statement/Prospectus included in the Registration Statement contains additional information about
this transaction, and is incorporated herein by reference. A copy of the Merger Agreement is attached as Exhibit&nbsp;2.1 to Genzyme's Current Report on Form&nbsp;8-K filed with the
SEC on February&nbsp;27, 2004, and is incorporated herein by reference. The foregoing discussion is qualified in its entirety by reference to such documents. </FONT></P>


<P><FONT SIZE=2><A
NAME="de2337_item_9.01._financial_statements_and_exhibits."> </A>
<A NAME="toc_de2337_2"> </A>
<BR></FONT><FONT SIZE=2><B>Item 9.01. Financial Statements and Exhibits.    <BR>    </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2><I>Financial Statements of Business Acquired.</I></FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genzyme
intends to provide the financial statements of ILEX for the periods specified in Rule&nbsp;3-05 of Regulation&nbsp;S-X under cover of a
Form&nbsp;8-K/A within the time allowed for such filing by Item 9.01(a)(4) of this Form. </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2><I>Pro Forma Financial Information.</I></FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genzyme
intends to provide pro forma financial information under cover of a Form&nbsp;8-K/A within the time allowed for such filing by Item 9.01(b)(2) of this Form. </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2><I>Exhibits</I></FONT><FONT SIZE=2>. </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Exhibit No.</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="89%" ALIGN="LEFT"><FONT SIZE=1><B>Description<BR> </B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%" ALIGN="CENTER"><FONT SIZE=2>2.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Agreement and Plan of Merger dated as of February 26, 2004 among Genzyme Corporation, GLBC Corp., GLBC LLC and ILEX Oncology, Inc. (incorporated herein by reference to Exhibit 2.1 to Genzyme's Current Report on Form 8-K
filed with the Securities and Exchange Commission on February 27, 2004).</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2147860",CP="GENZYME CORPORATION",DN="1",CHK=15650,FOLIO='blank',FILE='DISK009:[04BOS7.04BOS2337]DE2337A.;7',USER='CJOHNSOC',CD='20-DEC-2004;18:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="jc2337_signature"> </A>
<A NAME="toc_jc2337_1"> </A>
<BR></FONT><FONT SIZE=2><B>SIGNATURE    <BR>    </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="42%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>GENZYME CORPORATION</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="42%"><FONT SIZE=2><BR>
Dated: December 20, 2004</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="51%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MICHAEL S. WYZGA</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Michael S. Wyzga<BR></FONT> <FONT SIZE=2><I>Executive Vice President, Finance;<BR>
Chief Financial Officer; and Chief Accounting Officer </I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2147860",CP="GENZYME CORPORATION",DN="1",CHK=724934,FOLIO='blank',FILE='DISK009:[04BOS7.04BOS2337]JC2337A.;6',USER='CJOHNSOC',CD='20-DEC-2004;18:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="je2337_exhibit_index"> </A>
<A NAME="toc_je2337_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT INDEX    <BR>    </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Exhibit No.</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="89%" ALIGN="LEFT"><FONT SIZE=1><B>Description<BR> </B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%" ALIGN="CENTER"><FONT SIZE=2>2.1</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Agreement and Plan of Merger dated as of February 26, 2004 among Genzyme Corporation, GLBC Corp., GLBC LLC and ILEX Oncology, Inc. (incorporated herein by reference to Exhibit 2.1 to Genzyme's Current Report on Form 8-K
filed with the Securities and Exchange Commission on February 27, 2004).</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2147860",CP="GENZYME CORPORATION",DN="1",CHK=365185,FOLIO='blank',FILE='DISK009:[04BOS7.04BOS2337]JE2337A.;5',USER='CJOHNSOC',CD='20-DEC-2004;18:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04BOS2337_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_de2337_1">Item 2.01. Completion of Acquisition or Disposition of Assets.</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_de2337_2">Item 9.01. Financial Statements and Exhibits.</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_jc2337_1">SIGNATURE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_je2337_1">EXHIBIT INDEX</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=TMCKINN,SEQ=,EFW="2147860",CP="GENZYME CORPORATION",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
